Sera PrognosticsSERA
About: Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
Employees: 57
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
96,000% more call options, than puts
Call options by funds: $961K | Put options by funds: $1K
50% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 12
41% more capital invested
Capital invested by funds: $99.7M [Q2] → $140M (+$40.7M) [Q3]
2.43% more ownership
Funds ownership: 53.1% [Q2] → 55.53% (+2.43%) [Q3]
6% less funds holding
Funds holding: 65 [Q2] → 61 (-4) [Q3]
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
Research analyst outlook
We haven’t received any recent analyst ratings for SERA.
Financial journalist opinion
Based on 6 articles about SERA published over the past 30 days
